CLINICAL_TRIALS
other
· 2026-01-23
Clinical Trial Update: Efficacy and Safety of LP-005 Injection in Patients With Complement-Mediated Kidney Disease [Phase 2]
Summary
The Phase 2 trial of LP-005 Injection for complement-mediated renal diseases has not yet begun recruiting.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Longbio Pharma | Conditions: Complement-mediated Renal Diseases | Phase 2 | Status: NOT_YET_RECRUITING